Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational cohort study is to establish a risk prediction model for adverse events in Chinese individuals under 45 years old with premature coronary artery disease. The main questions it aims to answer are:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| MACCE, defined as a composite of cardiac death, MI, ischemic stroke, and repeat revascularization | 2 years | |
| Sensitivity for 2-year MACCE prediction | For the validation cohort | 2 years |
| Specificity for 2-year MACCE prediction | For the validation cohort | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of death (cardiovascular, noncardiovascular, and undetermined) at 1 m, 6 m, 1 y and 2 y | For the development cohort | 2 years |
| Incidence of MI (target vessel related and non-target vessel related or Culprit and non-culprit lesion-related) at 1 m, 6 m, 1 y and 2 y |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Eligible participants are CAD patients aged 18-45 years confirmed by coronary angiography or other imaging modalities, including those with stable/unstable angina or myocardial infarction.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jingjing Xu | Contact | 86 134-260-50924 | 335418449@qq.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| FuWai Hospital | Recruiting | Beijing | China |
Not provided
Not provided
Not provided
Not provided
For the development cohort |
| 2 years |
| Incidence of all revascularizations (ischemia driven vs. non-ischemia driven; Target vs. non-target vessel; Culprit vs. non-culprit lesion) at 1 m, 6 m, 1 y and 2 y | For the development cohort | 2 years |
| Incidence of definite or probable stent thrombosis during the acute, subacute, late, and very late phase according to the ARC-2 criteria | For the development cohort | 2 years |
| Incidence of stroke (ischemic and hemorrhagic stroke) at 1 m, 6 m, 1 y and 2 y | For the development cohort | 2 years |
| Incidence of bleeding events defined as BARC type ≥2 at 1 m, 6 m, 1 y and 2 y | For the development cohort | 2 years |
| Area under the ROC curve (AUC) | For the validation cohort | 2 years |
| Positive predictive value (PPV) | For the validation cohort | 2 years |
| Negative predictive value (NPV) | For the validation cohort | 2 years |